Prediction of Thorough QT Trials based on Population Pharmacokinetic: Pharmacodynamic Analysis of Phase I Study QT Data

被引：0
|
作者：
Trame, Mirjam N.
Vik, Torbjorn [1 ,2 ]
Hamren, Ulrika Wahlby [3 ]
Henriksson, Karin M. [4 ,5 ]
Friberg, Lena E.
机构：
[1] Uppsala Univ, Pharmacometr Res Grp, Dept Pharmaceut Biosci, Uppsala, Sweden
[2] AstraZeneca R&D, AZ ECG Ctr, Molndal, Sweden
[3] AstraZeneca R&D, Clin Pharmacol & Pharmacometr, Molndal, Sweden
[4] Dept Med Sci, Uppsala, Sweden
[5] AstraZeneca R&D, Dept Epidemiol, Molndal, Sweden
来源：
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS | 2013年 / 40卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：S78 / S79
页数：2
相关论文
共 50 条
  • [41] A Population Pharmacokinetic and Pharmacodynamic Analysis of RP5063 Phase 2 Study Data in Patients with Schizophrenia or Schizoaffective Disorder
    Cantillon, Marc
    Ings, Robert
    Prakash, Arul
    Bhat, Laxminarayan
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2018, 43 (05) : 573 - 585
  • [42] A Population Pharmacokinetic and Pharmacodynamic Analysis of RP5063 Phase 2 Study Data in Patients with Schizophrenia or Schizoaffective Disorder
    Marc Cantillon
    Robert Ings
    Arul Prakash
    Laxminarayan Bhat
    European Journal of Drug Metabolism and Pharmacokinetics, 2018, 43 : 573 - 585
  • [43] Pharmacokinetic-pharmacodynamic analysis to evaluate the effect of moxifloxacin on QT interval prolongation in healthy Korean male subjects
    Hong, Taegon
    Han, Seunghoon
    Lee, Jongtae
    Jeon, Sangil
    Park, Gab-Jin
    Park, Wan-Su
    Lim, Kyoung Soo
    Chung, Jae-Yong
    Yu, Kyung-Sang
    Yim, Dong-Seok
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 1233 - 1245
  • [44] Population-based beat-to-beat QT analysis from Holter recordings in the long QT syndrome
    Page, Alex
    McNitt, Scott
    Xia, Xiaojuan
    Zareba, Wojciech
    Couderc, Jean-Philippe
    JOURNAL OF ELECTROCARDIOLOGY, 2017, 50 (06) : 787 - 791
  • [45] Consideration of QT/QTc interval data in a phase I study in patients with advanced cancer. Reply
    Cooney, M
    Radivoyevitch, T
    Dowlati, A
    Overmoyer, B
    Levitan, N
    Robertson, K
    Remick, SC
    Stambler, BS
    CLINICAL CANCER RESEARCH, 2004, 10 (17) : 5968 - 5969
  • [46] Population-based approach to the assessment of pharmacokinetic-pharmacodynamic data
    Troconiz, IF
    METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 1996, 18 : 51 - 52
  • [47] POPULATION PHARMACOKINETIC AND PHARMACODYNAMIC MODELLING OF MIM8 BASED ON CLINICAL PHASE 1/2 DATA
    Kreilgaard, M.
    Jorgensen, P. J.
    Matytsina, I.
    Persson, P.
    HAEMOPHILIA, 2023, 29 : 88 - 89
  • [48] A phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin.
    Thomas, JP
    Schiller, J
    Lee, F
    Perlman, S
    Friedl, A
    Winter, T
    Marnocha, R
    Arzoomanian, R
    Alberti, D
    Binger, K
    Volkman, J
    Feierabend, C
    Tutsch, K
    Dresen, A
    Auerbach, R
    Pluda, J
    Wilding, G
    CLINICAL CANCER RESEARCH, 2000, 6 : 4518S - 4518S
  • [49] Concentration-QT analysis of the randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects
    Rashmi Mehta
    Michelle Green
    Bela Patel
    Jonathan Wagg
    Journal of Pharmacokinetics and Pharmacodynamics, 2016, 43 : 153 - 164
  • [50] Concentration-QT analysis of the randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects
    Mehta, Rashmi
    Green, Michelle
    Patel, Bela
    Wagg, Jonathan
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2016, 43 (02) : 153 - 164
12345